{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:25:09Z","timestamp":1794864309911,"version":"4.9.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006186","name":"Deutsche Gesellschaft f\u00fcr Urologie","doi-asserted-by":"publisher","award":["Ferdinand Eisenberger-Stipendium"],"award-info":[{"award-number":["Ferdinand Eisenberger-Stipendium"]}],"id":[{"id":"10.13039\/501100006186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2016.041.1\/.2\/.3"],"award-info":[{"award-number":["2016.041.1\/.2\/.3"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["NE1861\/8-1"],"award-info":[{"award-number":["NE1861\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Being stimulated by the chemokine CXCL12, the CXCR4\u00a0\/\u00a0CXCR7 cascade is involved in tumor proliferation, migration, and metastasis. The interaction between CXCL12, secreted by cells from the microenvironment, and its receptors is complex and has been ascribed to promote chemotherapy resistance. However, the role of this signaling axis and its targetability in germ cell tumors (GCT) is not fully understood. Thus, this study investigated the therapeutic efficacy of a nanobody-drug-conjugate targeting CXCR4 (CXCR4-NDC) and functionally characterized this signaling pathway in GCT using small molecule inhibitors and nanobodies. As shown by diminished cell viability, enhanced apoptosis induction, and detection of mitotic catastrophes, we confirmed the cytotoxic efficacy of the CXCR4-NDC in CXCR4<jats:sup>+<\/jats:sup>-GCT cells (i.e. seminoma and yolk-sac tumor), while non-malignant CXCR4<jats:sup>\u2212<\/jats:sup>-fibroblasts, remained largely unaffected. Stimulation of CXCR4<jats:sup>+<\/jats:sup>\u00a0\/\u00a0CXCR7<jats:sup>+<\/jats:sup>-GCT cells with CXCL12 resulted in an enhanced proliferative and migratory capacity, while this effect could be reverted using CXCR4 inhibitors or a CXCR7-nanobody. Molecularly, the CXCR4\u00a0\/\u00a0CXCR7-signaling cascade could be activated independently of MAPK (ERK1\u00a0\/\u00a02)-phosphorylation. Although, in CXCR4<jats:sup>\u2212<\/jats:sup>\u00a0\/\u00a0CXCR7<jats:sup>\u2212<\/jats:sup>-embryonal carcinoma cells, <jats:italic>CXCR7<\/jats:italic>-expression was re-induced upon inhibition of ERK1\u00a0\/\u00a02-signaling. This study identified a nanobody-drug-conjugate targeting CXCR4 as a putative therapeutic option for GCT, i.e. seminoma and yolk-sac tumors. Furthermore, this study shed light on the functional role of the CXCR4\u00a0\/\u00a0CXCR7\u00a0\/\u00a0CXCL12-signaling cascade in GCT, demonstrating an important influence on proliferation and migration.<\/jats:p>","DOI":"10.1186\/s40164-023-00460-9","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T14:02:38Z","timestamp":1700748158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular characterization of the CXCR4\u00a0\/\u00a0CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates"],"prefix":"10.1186","volume":"12","author":[{"given":"Gamal A.","family":"Wakileh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Bierholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Kotthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretha A.","family":"Skowron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bremmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Anbuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimond","family":"Heukers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Str\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nettersheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"460_CR1","doi-asserted-by":"crossref","unstructured":"Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2014;65(6):1095\u2013106.","DOI":"10.1016\/j.eururo.2013.11.004"},{"issue":"4","key":"460_CR2","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/1878-0261.13066","volume":"16","author":"MA Skowron","year":"2021","unstructured":"Skowron MA, Becker TK, Kurz L, Jostes S, Bremmer F, Fronhoffs F, et al. The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas. Mol Oncol. 2021;16(4):982\u20131008.","journal-title":"Mol Oncol"},{"issue":"1","key":"460_CR3","doi-asserted-by":"publisher","first-page":"15920","DOI":"10.1038\/s41598-017-15674-1","volume":"7","author":"MP Johansson","year":"2017","unstructured":"Johansson MP, Maaheimo H, Ekholm FS. New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling. Sci Rep. 2017;7(1):15920.","journal-title":"Sci Rep"},{"issue":"7","key":"460_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jmcb\/mjz060","volume":"11","author":"Y Liu","year":"2019","unstructured":"Liu Y, Tavana O, Gu W. p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019;11(7):564\u201377.","journal-title":"J Mol Cell Biol"},{"issue":"11","key":"460_CR5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.molmed.2010.09.002","volume":"16","author":"C Dai","year":"2010","unstructured":"Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med. 2010;16(11):528\u201336.","journal-title":"Trends Mol Med"},{"issue":"5","key":"460_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1124\/molpharm.120.000056","volume":"98","author":"C Koch","year":"2020","unstructured":"Koch C, Engele J. Functions of the CXCL12 receptor ACKR3\/CXCR7-What has been Perceived and what has been overlooked. Mol Pharmacol. 2020;98(5):577\u201385.","journal-title":"Mol Pharmacol"},{"issue":"24","key":"460_CR7","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1182\/blood-2008-12-196618","volume":"113","author":"A Levoye","year":"2009","unstructured":"Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood. 2009;113(24):6085\u201393.","journal-title":"Blood"},{"key":"460_CR8","doi-asserted-by":"publisher","first-page":"591386","DOI":"10.3389\/fonc.2021.591386","volume":"11","author":"S Santagata","year":"2021","unstructured":"Santagata S, Ieran\u00f2 C, Trotta AM, Capiluongo A, Auletta F, Guardascione G, et al. CXCR4 and CXCR7 signaling pathways: a focus on the Cross-talk between Cancer cells and Tumor Microenvironment. Front Oncol. 2021;11:591386.","journal-title":"Front Oncol"},{"key":"460_CR9","doi-asserted-by":"publisher","first-page":"574667","DOI":"10.3389\/fphar.2020.574667","volume":"11","author":"Y Shi","year":"2020","unstructured":"Shi Y, Riese DJ, Shen J. The role of the CXCL12\/CXCR4\/CXCR7 Chemokine Axis in Cancer. Front Pharmacol. 2020;11:574667.","journal-title":"Front Pharmacol"},{"key":"460_CR10","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.phrs.2020.105092","volume":"161","author":"C Huynh","year":"2020","unstructured":"Huynh C, Dingemanse J, Meyer zu Schwabedissen HE, Sidharta PN. Relevance of the CXCR4\/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. Pharmacol Res. 2020;161:105092.","journal-title":"Pharmacol Res"},{"issue":"3","key":"460_CR11","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1111\/jcmm.16222","volume":"25","author":"W Wruck","year":"2021","unstructured":"Wruck W, Bremmer F, Kotthoff M, Fichtner A, Skowron MA, Sch\u00f6nberger S, et al. The pioneer and differentiation factor FOXA2 is a key driver of yolk-sac tumour formation and a new biomarker for paediatric and adult yolk-sac tumours. J Cell Mol Med. 2021;25(3):1394\u2013405.","journal-title":"J Cell Mol Med"},{"key":"460_CR12","doi-asserted-by":"crossref","unstructured":"S\u00f6hngen C, Thomas DJ, Skowron MA, Bremmer F, Eckstein M, Stefanski A, et al. CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) Bladder cancer and identification of direct CD24 interaction partners. FEBS J. 2023;290(20):4864\u2013876.","DOI":"10.1111\/febs.16880"},{"issue":"1","key":"460_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10020-023-00636-3","volume":"29","author":"MA Skowron","year":"2023","unstructured":"Skowron MA, Kotthoff M, Bremmer F, Ruhnke K, Parmaksiz F, Richter A, et al. Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options. Mol Med. 2023;29(1):40.","journal-title":"Mol Med"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00460-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00460-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00460-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T14:05:24Z","timestamp":1700748324000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00460-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00460-9","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"24 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of the Heinrich Heine University D\u00fcsseldorf\u00a0(HHU-D) raised no concerns on utilizing cell lines for in vitro experiments (vote 2018\u2009\u2212\u2009178 to D. N.). The ethics committees of the HHU-D and the University Medical Center G\u00f6ttingen\u00a0(UMG) raised no concerns on performing the described experiments on GCT tissues from local biobanks (vote 2020.1247(_1) to D. N.; vote 20\/09\/20 to F. B., vote 24\/4\/20 to P.\u00a0S.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors are aware of this article and agreed on publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}